The Unique Investment Opportunity
Why Our Drug Design Approach is Unique
Our drug is designed to bind only when our target is shed from the cancer tumor cell:
- Target is found in both blood cancers and solid tumors
- Safety is built-in, less toxicity expected
- Stimulates immune system rather than targeting tumor cells directly
- Balanced approach predicted to “not” over-stimulate immune system
- Limits further immune suppression induced by shed ligands
- No overlapping MOA (mechanism of action)….potential for other therapeutic combinations (large pharma has huge interest in single and combo therapies)
Things You May Want to Know:
What are Immunotherapy Drugs?
Note: We are a Monoclonal Antibody Drug
Top 15 Immuno-Oncology Collaborations
Which Biopharmas Have Spent the Most on Cancer Immunotherapy Partnerships?